OnKure Therapeutics

OnKure Therapeutics

OnKure Therapeutics launched in 2011 after Nicholas Saccomano, a former Array BioPharma and SomaLogic scientist, licensed foundational chemistry from the University of Colorado Boulder. The company's original focus was narrow: develop selective histone deacetylase inhibitors for cancers driven by specific epigenetic lesions, an area where broad-spectrum HDAC inhibitors had produced clinical responses but also dose-limiting toxicities. Early venture backing from Delian Capital and other life-science specialists funded a platform that has since expanded into phosphoinositide 3-kinase (PI3K) inhibitors. The firm's pipeline is built around two clinical-stage assets. OKI-179, an oral Class I HDAC inhibitor, has completed Phase 1 dose-escalation in advanced solid tumors and combines with binimetinib in NRAS-mutant melanoma. OKI-219, a mutant-selective PI3K-alpha H1047R inhibitor, targets one of the most common oncogenic driver mutations in breast cancer and entered the clinic in 2023. OnKure structures itself as a drug development engine rather than a discovery platform, in-licensing or acquiring assets that align with its translational biology team in Boulder, Colorado. The workforce is concentrated at the Boulder headquarters, where Saccomano manages a lean team of clinical and chemistry professionals. In May 2024 the firm merged with Reneo Pharmaceuticals in an all-stock transaction that effectively took OnKure public on Nasdaq under the ticker OKUR, providing Reneo's cash reserves for the Phase 1 work on OKI-219. The combined entity retained the OnKure name and pipeline. OnKure's structure sets it apart from most clinical-stage oncology companies because its pipeline was assembled through in-licensing and merger rather than internal target discovery. The Reneo reverse-merger was a capital-markets arbitrage that avoided a conventional biotech IPO roadshow, a model that several cash-constrained biotechs are now following. The firm's governance remains scientist-led, with Saccomano retaining control of R&D strategy while the merged company reports through public-market compliance channels.